David A. Foster to Antibiotics, Antineoplastic
This is a "connection" page, showing publications David A. Foster has written about Antibiotics, Antineoplastic.
Connection Strength
1.194
-
Mukhopadhyay S, Frias MA, Chatterjee A, Yellen P, Foster DA. The Enigma of Rapamycin Dosage. Mol Cancer Ther. 2016 Mar; 15(3):347-53.
Score: 0.535
-
Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle. 2009 Apr 01; 8(7):1026-9.
Score: 0.332
-
Chatterjee A, Mukhopadhyay S, Tung K, Patel D, Foster DA. Rapamycin-induced G1 cell cycle arrest employs both TGF-? and Rb pathways. Cancer Lett. 2015 May 01; 360(2):134-40.
Score: 0.124
-
Mukhopadhyay S, Chatterjee A, Kogan D, Patel D, Foster DA. 5-Aminoimidazole-4-carboxamide-1-?-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells. Cell Cycle. 2015; 14(20):3331-9.
Score: 0.124
-
Foster DA, Gadir N. [Can defective TGF-Beta signaling be an Achilles heel in human cancer?]. Ai Zheng. 2008 Aug; 27(8):882-4.
Score: 0.079